Bud Selig AP

Major League Baseball issues a statement about the A-Rod therapeutic use exemptions. But questions remain.

23 Comments

source: AP

Earlier today a book excerpt was released in which it was revealed that Alex Rodriguez received therapeutic use exemptions from Major League Baseball for performance enhancing drugs, including testosterone, for at least the 2007 and 2008 seasons.

A few moments ago, Major League Baseball issued the following statement:

“All decisions regarding whether a player shall receive a therapeutic use exemption (TUE) under the Joint Drug Program are made by the Independent Program Administrator (IPA) in consultation with outside medical experts, with no input by either the Office of the Commissioner or the Players Association. The process is confidentially administered by the IPA, and MLB and the MLBPA are not even made aware of which players applied for TUEs.

“The TUE process under the Joint Drug Program is comparable to the process under the World Anti-Doping Code. The standard for receiving a TUE for a medication listed as a performance-enhancing substance is stringent, with only a few such TUEs being issued each year by the IPA. MLB and the MLBPA annually review the TUE process to make sure it meets the most up-to-date standards for the issuance of TUEs.

“As recommended by the Mitchell Report, since 2008 MLB and the MLBPA have publicly issued the IPA’s annual report, which documents how many TUEs were granted for each category of medication. We believe this high level of transparency helps to ensure the proper operation of the TUE process.”

One can’t take issue with any of the facts asserted in that statement. However, the “since 2008” thing about TUE allowances doesn’t address what A-Rod was doing in 2007, which is when it was reported he received a TUE for testosterone. Also, the reference to the Independent Program Administrator and his or her consultations with “outside medical experts” ignores the fact that, per the excerpt in the book, baseball did not yet have an expert medical panel to advise the IPA in 2007.

So, yes, the system for TUE may be excellent now. But it was not the same in 2007 and before, and I believe the claims in the book excerpt still raise some interesting questions about how baseball handled such matters in the past and what — and why — A-Rod was allowed to take legally before he turned to illegal means to obtain performance enhancing drugs.

Dodgers sign Rich Hill to a three-year, $48 million deal

LOS ANGELES, CA - OCTOBER 18:  Rich Hill #44 of the Los Angeles Dodgers pitches in the first inning against the Chicago Cubs in game three of the National League Championship Series at Dodger Stadium on October 18, 2016 in Los Angeles, California.  (Photo by Harry How/Getty Images)
Getty Images
Leave a comment

The Dodgers have signed lefty Rich Hill to a three-year, $48 million contract.The deal was reported to be imminent over the weekend, but was finalized today following Hill’s physical.

Hill missed a good deal of time in 2016 with blister issues — and he’ll be 37-years-old on Opening Day — but when he was healthy he was fantastic, posting the best season in his 12-year career. He had a a 2.12 ERA and 129 strikeouts in 110.1 innings between the Athletics and Dodgers.

Along with a healthy Clayton Kershaw a maturing Julio Urias and Kenta Maeda, the Dodgers rotation looks to be a strength in 2017.

UPDATE: Giants agree to a deal with Mark Melancon

LOS ANGELES, CA - OCTOBER 10:  Mark Melancon #43 of the Washington Nationals reacts after the final out as the Nationals defeat the Los Angeles Dodgers 8-3 in game three of the National League Division Series at Dodger Stadium on October 10, 2016 in Los Angeles, California.  (Photo by Jeff Gross/Getty Images)
Getty Images
3 Comments

UPDATE: Buster Olney reports that a deal is in place pending a physical. The financial terms are not yet known. UPDATE: Joel Sherman of the New York Post hears it’s in the four-year, $62 million range. That will make him, temporarily at least, the highest-paid closer in baseball history.

12:15 PMKen Rosenthal reports that the San Francisco Giants are close to a deal with closer Mark Melancon.

Melancon had an outstanding 2016, posting a 1.64 ERA, 2.42 FIP and a 5.42 K/BB rate in 71.1 innings while saving 47 games for the Pirates and Nationals. You may recall that the Giants had a strong interest in Melancon last summer. It was a well-founded interest given the bullpen woes which waylaid San Francisco in the second half of last season and continued on into the playoffs.

The terms of the apparently impeding deal will be known soon enough, but Rosenthal reported yesterday that Melancon was fielding offers in the four-years, $60 million range. That’s a lot for a closer, but it’ll probably look like a bargain compared to the deals signed with the other two top closers on the market, Aroldis Chapman and Kenley Jansen. Some have speculated that Chapman could get a deal closer to $100 million than $50 million, though that seems optimistic.

What the past couple of seasons have shown, however, is that having a top bullpen will get you very, very far in Major League Baseball. Champan may have been gassed at the end of Game 7, but he was essential to the Cubs’ World Series title. Powerful bullpens gave the Royals a title in 2015 and the Indians an AL pennant this past year. A weak one was, obviously, the Giants’ achilles heel.

Their great need at the back end of the pen, according to Rosenthal’s report, is apparently about to be filled.